These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24131719)

  • 21. HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers.
    Nyanhete TE; Frisbee AL; Bradley T; Faison WJ; Robins E; Payne T; Freel SA; Sawant S; Weinhold KJ; Wiehe K; Haynes BF; Ferrari G; Li QJ; Moody MA; Tomaras GD
    Sci Rep; 2019 Jul; 9(1):10165. PubMed ID: 31308388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control.
    Hersperger AR; Pereyra F; Nason M; Demers K; Sheth P; Shin LY; Kovacs CM; Rodriguez B; Sieg SF; Teixeira-Johnson L; Gudonis D; Goepfert PA; Lederman MM; Frank I; Makedonas G; Kaul R; Walker BD; Betts MR
    PLoS Pathog; 2010 May; 6(5):e1000917. PubMed ID: 20523897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.
    Hunt PW; Hatano H; Sinclair E; Lee TH; Busch MP; Martin JN; McCune JM; Deeks SG
    Clin Infect Dis; 2011 Mar; 52(5):681-7. PubMed ID: 21245154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants.
    Pohlmeyer CW; Buckheit RW; Siliciano RF; Blankson JN
    Retrovirology; 2013 Dec; 10():152. PubMed ID: 24330837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Escape Mutant-Specific T Cells in Suppression of HIV-1 Replication and Coevolution with HIV-1.
    Zhang Y; Kuse N; Akahoshi T; Chikata T; Gatanaga H; Oka S; Murakoshi H; Takiguchi M
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers.
    Ndhlovu ZM; Stampouloglou E; Cesa K; Mavrothalassitis O; Alvino DM; Li JZ; Wilton S; Karel D; Piechocka-Trocha A; Chen H; Pereyra F; Walker BD
    J Virol; 2015 Nov; 89(21):10735-47. PubMed ID: 26269189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.
    Migueles SA; Sabbaghian MS; Shupert WL; Bettinotti MP; Marincola FM; Martino L; Hallahan CW; Selig SM; Schwartz D; Sullivan J; Connors M
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2709-14. PubMed ID: 10694578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of TI8-8V mutant associated with long-term control of HIV-1 by cross-reactive HLA-B*51:01-restricted cytotoxic T cells.
    Kuse N; Akahoshi T; Gatanaga H; Ueno T; Oka S; Takiguchi M
    J Immunol; 2014 Nov; 193(10):4814-22. PubMed ID: 25305317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD8
    Murakoshi H; Zou C; Kuse N; Akahoshi T; Chikata T; Gatanaga H; Oka S; Hanke T; Takiguchi M
    Retrovirology; 2018 Jul; 15(1):46. PubMed ID: 29970102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection.
    Addo MM; Draenert R; Rathod A; Verrill CL; Davis BT; Gandhi RT; Robbins GK; Basgoz NO; Stone DR; Cohen DE; Johnston MN; Flynn T; Wurcel AG; Rosenberg ES; Altfeld M; Walker BD
    PLoS One; 2007 Mar; 2(3):e321. PubMed ID: 17389912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA B*5701-positive long-term nonprogressors/elite controllers are not distinguished from progressors by the clonal composition of HIV-specific CD8+ T cells.
    Mendoza D; Royce C; Ruff LE; Ambrozak DR; Quigley MF; Dang T; Venturi V; Price DA; Douek DC; Migueles SA; Connors M
    J Virol; 2012 Apr; 86(7):4014-8. PubMed ID: 22278241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control.
    Murakoshi H; Koyanagi M; Akahoshi T; Chikata T; Kuse N; Gatanaga H; Rowland-Jones SL; Oka S; Takiguchi M
    EBioMedicine; 2018 Oct; 36():103-112. PubMed ID: 30249546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient.
    Brener J; Gall A; Hurst J; Batorsky R; Lavandier N; Chen F; Edwards A; Bolton C; Dsouza R; Allen T; Pybus OG; Kellam P; Matthews PC; Goulder PJR
    Retrovirology; 2018 Jan; 15(1):7. PubMed ID: 29338738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition.
    Miura T; Brockman MA; Schneidewind A; Lobritz M; Pereyra F; Rathod A; Block BL; Brumme ZL; Brumme CJ; Baker B; Rothchild AC; Li B; Trocha A; Cutrell E; Frahm N; Brander C; Toth I; Arts EJ; Allen TM; Walker BD
    J Virol; 2009 Mar; 83(6):2743-55. PubMed ID: 19116253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers.
    Lambotte O; Pollara J; Boufassa F; Moog C; Venet A; Haynes BF; Delfraissy JF; Saez-Cirion A; Ferrari G
    PLoS One; 2013; 8(9):e74855. PubMed ID: 24086385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunodominant HIV-1-specific HLA-B- and HLA-C-restricted CD8+ T cells do not differ in polyfunctionality.
    Mkhwanazi N; Thobakgale CF; van der Stok M; Reddy S; Mncube Z; Chonco F; Walker BD; Altfeld M; Goulder PJ; Ndung'u T
    Virology; 2010 Sep; 405(2):483-91. PubMed ID: 20638093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.
    Lambotte O; Boufassa F; Madec Y; Nguyen A; Goujard C; Meyer L; Rouzioux C; Venet A; Delfraissy JF;
    Clin Infect Dis; 2005 Oct; 41(7):1053-6. PubMed ID: 16142675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of HIV-1 Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57: 01 Is Only Observed in Viremic Controllers.
    Tjiam MC; Morshidi MA; Sariputra L; Martin JN; Deeks SG; Tan DBA; Lee S; Fernandez S; French MA
    J Acquir Immune Defic Syndr; 2017 Nov; 76(3):e90-e92. PubMed ID: 28604502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.
    Altfeld M; Addo MM; Rosenberg ES; Hecht FM; Lee PK; Vogel M; Yu XG; Draenert R; Johnston MN; Strick D; Allen TM; Feeney ME; Kahn JO; Sekaly RP; Levy JA; Rockstroh JK; Goulder PJ; Walker BD
    AIDS; 2003 Dec; 17(18):2581-91. PubMed ID: 14685052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.
    Van Gulck E; Bracke L; Heyndrickx L; Coppens S; Atkinson D; Merlin C; Pasternak A; Florence E; Vanham G
    PLoS One; 2012; 7(5):e37792. PubMed ID: 22666392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.